A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Minsk, Belarus
-
-
-
-
-
Brussels, Belgium
-
Genk, Belgium
-
-
-
-
-
Banja Luka, Bosnia and Herzegovina
-
Mostar, Bosnia and Herzegovina
-
Sarajevo, Bosnia and Herzegovina
-
Tuzla, Bosnia and Herzegovina
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Alberta, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Ontario
-
Oshawa, Ontario, Canada
-
Thunder Bay, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
Sherbrooke, Quebec, Canada
-
-
-
-
-
Antofagasta, Chile
-
Osorno, Chile
-
Santiago, Chile
-
Temuco, Chile
-
-
-
-
-
Daugavpils, Latvia
-
Riga, Latvia
-
Ventspils, Latvia
-
-
-
-
-
Cordoba, Mexico
-
Guadalajara Jalisco, Mexico
-
Mexico City, Mexico
-
-
-
-
-
Chisinau, Moldova, Republic of
-
-
-
-
-
Arkhangelsk, Russian Federation
-
Barnaul, Russian Federation
-
Chelyabinsk, Russian Federation
-
Ivanovo, Russian Federation
-
Kaliningrad, Russian Federation
-
Kazan, Russian Federation
-
Kemerovo, Russian Federation
-
Krasnodar, Russian Federation
-
Krasnoyarsk, Russian Federation
-
Moscow, Russian Federation
-
N.Novgorod, Russian Federation
-
Novosibirsk, Russian Federation
-
Orenburg, Russian Federation
-
Penza, Russian Federation
-
Perm, Russian Federation
-
Rostov on Don, Russian Federation
-
Samara, Russian Federation
-
Saratov, Russian Federation
-
St. Petersburg, Russian Federation
-
Tomsk, Russian Federation
-
Tula, Russian Federation
-
Tyumen, Russian Federation
-
Volgograd, Russian Federation
-
Yaroslavl, Russian Federation
-
-
-
-
-
Bardejov, Slovakia
-
Bratislava, Slovakia
-
Kosice, Slovakia
-
Lucenec, Slovakia
-
Presov, Slovakia
-
-
-
-
-
Cherkassy, Ukraine
-
Chernigov, Ukraine
-
Chernivtsy, Ukraine
-
Dnepropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Ivano-Frankovsk, Ukraine
-
Kiev, Ukraine
-
Lutsk, Ukraine
-
Lviv, Ukraine
-
Odessa, Ukraine
-
Poltava, Ukraine
-
Ternopil, Ukraine
-
Vinnitsa, Ukraine
-
Zaporozhye, Ukraine
-
-
-
-
Alabama
-
Huntsville, Alabama, United States
-
-
California
-
Anaheim, California, United States
-
Beverly Hills, California, United States
-
Stockton, California, United States
-
-
Florida
-
Orlando, Florida, United States
-
Sarasota, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Canton, Georgia, United States
-
-
Indiana
-
Fort Wayne, Indiana, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
-
Michigan
-
Cadillac, Michigan, United States
-
-
Montana
-
Kalispell, Montana, United States
-
-
Nebraska
-
Fremont, Nebraska, United States
-
-
New Mexico
-
Santa Fe, New Mexico, United States
-
-
New York
-
Albany, New York, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
-
Pottstown, Pennsylvania, United States
-
Sellersville, Pennsylvania, United States
-
-
Texas
-
Dallas, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Washington
-
Bellevue, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 to 80 years old.
- Able to provide written informed consent.
- Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)
- A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2
Exclusion Criteria:
- Subjects with mitral valve disease or previous valvular heart surgery
- Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin
- Known or suspected hereditary or acquired bleeding or coagulation disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
DU-176b 30mg tablet once daily
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Experimental: 2
DU-176b 60mg once daily
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Experimental: 3
DU-176b 30mg b.i.d.
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Experimental: 4
DU-176b 60mg tablets two times a day
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Active Comparator: 5
warfarin tablets
|
warfarin tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjudicated Incidence of Bleeding Events
Time Frame: 3 months
|
Adjudicated Incidence of Bleeding Events during treatment period
|
3 months
|
|
Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)
Time Frame: 3 months
|
liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Major Adverse Cardiac Events MACE)
Time Frame: 3 months
|
MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition
|
3 months
|
|
Effects on Biomarker D-dimer
Time Frame: 3 months
|
Mean (SD) change from baseline in D-dimer
|
3 months
|
|
Effects on Biomarker Prothrombin Fragments
Time Frame: 3 months
|
Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)
|
3 months
|
|
Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b
Time Frame: 3 months
|
Median (min, max) values of Cmin,ss; Cmax,ss
|
3 months
|
|
Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b
Time Frame: 3 months
|
Median (min, max) values of AUCss
|
3 months
|
|
Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b
Time Frame: Day 28
|
Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b
Time Frame: Day 28
|
Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b
Time Frame: Day 28
|
Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose. PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition. |
Day 28
|
|
Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b
Time Frame: Day 28
|
Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b
Time Frame: Day 28
|
Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.
|
Day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Thromboembolism
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Edoxaban
- Warfarin
Other Study ID Numbers
Other Study ID Numbers
- DU176b-PRT018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.